Proactiveinvestors USA & Canada Antibe Therapeutics Inc https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Antibe Therapeutics Inc RSS feed en Sat, 05 Dec 2020 05:56:12 -0500 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Antibe Therapeutics strengthens governance and US capital markets expertise with appointments of two independent directors https://www.proactiveinvestors.com/companies/news/934792/antibe-therapeutics-strengthens-governance-and-us-capital-markets-expertise-with-appointments-of-two-independent-directors-934792.html Tue, 24 Nov 2020 14:29:00 -0500 https://www.proactiveinvestors.com/companies/news/934792/antibe-therapeutics-strengthens-governance-and-us-capital-markets-expertise-with-appointments-of-two-independent-directors-934792.html Antibe Therapeutics ends fiscal 2Q with C$22.4M in cash ahead of Phase III trial of lead drug otenaproxesul https://www.proactiveinvestors.com/companies/news/933947/antibe-therapeutics-ends-fiscal-2q-with-c224m-in-cash-ahead-of-phase-iii-trial-of-lead-drug-otenaproxesul-933947.html Fri, 13 Nov 2020 14:59:00 -0500 https://www.proactiveinvestors.com/companies/news/933947/antibe-therapeutics-ends-fiscal-2q-with-c224m-in-cash-ahead-of-phase-iii-trial-of-lead-drug-otenaproxesul-933947.html Antibe’s breakthrough osteoarthritis pain relief drug in the spotlight on World Arthritis Day https://www.proactiveinvestors.com/companies/news/931153/antibes-breakthrough-osteoarthritis-pain-relief-drug-in-the-spotlight-on-world-arthritis-day-931153.html Mon, 12 Oct 2020 11:30:00 -0400 https://www.proactiveinvestors.com/companies/news/931153/antibes-breakthrough-osteoarthritis-pain-relief-drug-in-the-spotlight-on-world-arthritis-day-931153.html Antibe Therapeutics plans to file IND with regulator for lead drug otenaproxesul https://www.proactiveinvestors.com/companies/news/927483/antibe-therapeutics-plans-to-file-ind-with-regulator-for-lead-drug-otenaproxesul-927483.html Tue, 25 Aug 2020 13:40:00 -0400 https://www.proactiveinvestors.com/companies/news/927483/antibe-therapeutics-plans-to-file-ind-with-regulator-for-lead-drug-otenaproxesul-927483.html Antibe Therapeutics releases data from company’s Phase II placebo-controlled efficacy study https://www.proactiveinvestors.com/companies/news/926500/antibe-therapeutics-releases-data-from-companys-phase-ii-placebo-controlled-efficacy-study-926500.html Wed, 12 Aug 2020 12:58:00 -0400 https://www.proactiveinvestors.com/companies/news/926500/antibe-therapeutics-releases-data-from-companys-phase-ii-placebo-controlled-efficacy-study-926500.html Antibe Therapeutics engages Stern IR to expand its investor relations program and broaden visibility within US capital markets https://www.proactiveinvestors.com/companies/news/926029/antibe-therapeutics-engages-stern-ir-to-expand-its-investor-relations-program-and-broaden-visibility-within-us-capital-markets-926029.html Thu, 06 Aug 2020 12:26:00 -0400 https://www.proactiveinvestors.com/companies/news/926029/antibe-therapeutics-engages-stern-ir-to-expand-its-investor-relations-program-and-broaden-visibility-within-us-capital-markets-926029.html Antibe Therapeutics says it has a clear path to billion-dollar revenue from its lead drug ATB-346 https://www.proactiveinvestors.com/companies/news/925805/antibe-therapeutics-says-it-has-a-clear-path-to-billion-dollar-revenue-from-its-lead-drug-atb-346-925805.html Tue, 04 Aug 2020 13:05:00 -0400 https://www.proactiveinvestors.com/companies/news/925805/antibe-therapeutics-says-it-has-a-clear-path-to-billion-dollar-revenue-from-its-lead-drug-atb-346-925805.html Antibe Therapeutics closes $28.75 million offering ahead of planned Phase 3 trial of ATB-346 https://www.proactiveinvestors.com/companies/news/923124/antibe-therapeutics-closes-2875-million-offering-ahead-of-planned-phase-3-trial-of-atb-346-923124.html Tue, 30 Jun 2020 14:52:00 -0400 https://www.proactiveinvestors.com/companies/news/923124/antibe-therapeutics-closes-2875-million-offering-ahead-of-planned-phase-3-trial-of-atb-346-923124.html Antibe Therapeutics unveils $25M bought deal offering to fund non-addictive analgesic drug pipeline https://www.proactiveinvestors.com/companies/news/921516/antibe-therapeutics-unveils-25m-bought-deal-offering-to-fund-non-addictive-analgesic-drug-pipeline-921516.html Tue, 09 Jun 2020 20:29:00 -0400 https://www.proactiveinvestors.com/companies/news/921516/antibe-therapeutics-unveils-25m-bought-deal-offering-to-fund-non-addictive-analgesic-drug-pipeline-921516.html Antibe Therapeutics unveils positive topline results from Phase 2B clinical trial of ATB-346 for osteoarthritis pain https://www.proactiveinvestors.com/companies/news/920832/antibe-therapeutics-unveils-positive-topline-results-from-phase-2b-clinical-trial-of-atb-346-for-osteoarthritis-pain-920832.html Mon, 01 Jun 2020 11:45:00 -0400 https://www.proactiveinvestors.com/companies/news/920832/antibe-therapeutics-unveils-positive-topline-results-from-phase-2b-clinical-trial-of-atb-346-for-osteoarthritis-pain-920832.html Antibe Therapeutics names former FDA official Dr Joseph Stauffer as chief medical officer https://www.proactiveinvestors.com/companies/news/918982/antibe-therapeutics-names-former-fda-official-dr-joseph-stauffer-as-chief-medical-officer-918982.html Wed, 06 May 2020 12:35:00 -0400 https://www.proactiveinvestors.com/companies/news/918982/antibe-therapeutics-names-former-fda-official-dr-joseph-stauffer-as-chief-medical-officer-918982.html Antibe Therapeutics expects results from Phase 2B study of pain drug ATB-346 within six weeks https://www.proactiveinvestors.com/companies/news/918749/antibe-therapeutics-expects-results-from-phase-2b-study-of-pain-drug-atb-346-within-six-weeks-918749.html Mon, 04 May 2020 12:55:00 -0400 https://www.proactiveinvestors.com/companies/news/918749/antibe-therapeutics-expects-results-from-phase-2b-study-of-pain-drug-atb-346-within-six-weeks-918749.html Antibe Therapeutics finishes Phase 2 trial for ATB-346; results expected in weeks https://www.proactiveinvestors.com/companies/news/916856/antibe-therapeutics-finishes-phase-2-trial-for-atb-346-results-expected-in-weeks-916856.html Tue, 07 Apr 2020 18:17:00 -0400 https://www.proactiveinvestors.com/companies/news/916856/antibe-therapeutics-finishes-phase-2-trial-for-atb-346-results-expected-in-weeks-916856.html Echelon rates Antibe Therapeutics as 'top pick' as investors eagerly await Phase II data from ATB-346 study https://www.proactiveinvestors.com/companies/news/916616/echelon-rates-antibe-therapeutics-as--top-pick--as-investors-eagerly-await-phase-ii-data-from-atb-346-study-916616.html Fri, 03 Apr 2020 16:52:00 -0400 https://www.proactiveinvestors.com/companies/news/916616/echelon-rates-antibe-therapeutics-as--top-pick--as-investors-eagerly-await-phase-ii-data-from-atb-346-study-916616.html American Council on Science and Health hails Antibe's ATB-346 as potential breakthrough in pain med https://www.proactiveinvestors.com/companies/news/914681/american-council-on-science-and-health-hails-antibe-s-atb-346-as-potential-breakthrough-in-pain-med-914681.html Tue, 10 Mar 2020 19:17:00 -0400 https://www.proactiveinvestors.com/companies/news/914681/american-council-on-science-and-health-hails-antibe-s-atb-346-as-potential-breakthrough-in-pain-med-914681.html NA Proactive news snapshot: Ozop Surgical, CytoDyn, Globex Mining, Heritage Cannabis UPDATE … https://www.proactiveinvestors.com/companies/news/913971/na-proactive-news-snapshot-ozop-surgical-cytodyn-globex-mining-heritage-cannabis-update--913971.html Fri, 28 Feb 2020 21:00:00 -0500 https://www.proactiveinvestors.com/companies/news/913971/na-proactive-news-snapshot-ozop-surgical-cytodyn-globex-mining-heritage-cannabis-update--913971.html Antibe Therapeutics enrolls last patient in Phase 2B dose-ranging study of lead drug ATB-346 https://www.proactiveinvestors.com/companies/news/913957/antibe-therapeutics-enrolls-last-patient-in-phase-2b-dose-ranging-study-of-lead-drug-atb-346-913957.html Fri, 28 Feb 2020 12:47:00 -0500 https://www.proactiveinvestors.com/companies/news/913957/antibe-therapeutics-enrolls-last-patient-in-phase-2b-dose-ranging-study-of-lead-drug-atb-346-913957.html Antibe Therapeutics reports positive progress in Phase 2B trials of ATB-346 https://www.proactiveinvestors.com/companies/news/913649/antibe-therapeutics-reports-positive-progress-in-phase-2b-trials-of-atb-346-913649.html Tue, 25 Feb 2020 15:05:00 -0500 https://www.proactiveinvestors.com/companies/news/913649/antibe-therapeutics-reports-positive-progress-in-phase-2b-trials-of-atb-346-913649.html Antibe Therapeutics sees article highlighting its anti-inflammatory drug published in medical journal https://www.proactiveinvestors.com/companies/news/913542/antibe-therapeutics-sees-article-highlighting-its-anti-inflammatory-drug-published-in-medical-journal-913542.html Mon, 24 Feb 2020 13:54:00 -0500 https://www.proactiveinvestors.com/companies/news/913542/antibe-therapeutics-sees-article-highlighting-its-anti-inflammatory-drug-published-in-medical-journal-913542.html Antibe Therapeutics bolsters executive team in preparation for ATB-346 commercialization https://www.proactiveinvestors.com/companies/news/910470/antibe-therapeutics-bolsters-executive-team-in-preparation-for-atb-346-commercialization-910470.html Mon, 13 Jan 2020 14:36:00 -0500 https://www.proactiveinvestors.com/companies/news/910470/antibe-therapeutics-bolsters-executive-team-in-preparation-for-atb-346-commercialization-910470.html NA Proactive news snapshot: Antibe Therapeutics, EuroLife Brands, Medgold Resources, NexTech AR Solutions UPDATE… https://www.proactiveinvestors.com/companies/news/908114/na-proactive-news-snapshot-antibe-therapeutics-eurolife-brands-medgold-resources-nextech-ar-solutions-update-908114.html Thu, 28 Nov 2019 21:30:00 -0500 https://www.proactiveinvestors.com/companies/news/908114/na-proactive-news-snapshot-antibe-therapeutics-eurolife-brands-medgold-resources-nextech-ar-solutions-update-908114.html Antibe Therapeutics running largest number of sites for any clinical trial in Canada in ATB-346 study https://www.proactiveinvestors.com/companies/news/908110/antibe-therapeutics-running-largest-number-of-sites-for-any-clinical-trial-in-canada-in-atb-346-study-908110.html Thu, 28 Nov 2019 13:41:00 -0500 https://www.proactiveinvestors.com/companies/news/908110/antibe-therapeutics-running-largest-number-of-sites-for-any-clinical-trial-in-canada-in-atb-346-study-908110.html Antibe Therapeutics is ready for a big push as it progresses pain management drug through clinical trials https://www.proactiveinvestors.com/companies/news/905097/antibe-therapeutics-is-ready-for-a-big-push-as-it-progresses-pain-management-drug-through-clinical-trials-905097.html Mon, 21 Oct 2019 13:00:00 -0400 https://www.proactiveinvestors.com/companies/news/905097/antibe-therapeutics-is-ready-for-a-big-push-as-it-progresses-pain-management-drug-through-clinical-trials-905097.html Antibe Therapeutics sees fiscal first quarter revenue rise thanks to higher sales in the United States https://www.proactiveinvestors.com/companies/news/901644/antibe-therapeutics-sees-fiscal-first-quarter-revenue-rise-thanks-to-higher-sales-in-the-united-states-901644.html Wed, 28 Aug 2019 13:35:00 -0400 https://www.proactiveinvestors.com/companies/news/901644/antibe-therapeutics-sees-fiscal-first-quarter-revenue-rise-thanks-to-higher-sales-in-the-united-states-901644.html Antibe Therapeutics: Phase 2B study of flagship drug ATB-346 to treat osteoarthritis pain ‘proceeding well’ https://www.proactiveinvestors.com/companies/news/901552/antibe-therapeutics-phase-2b-study-of-flagship-drug-atb-346-to-treat-osteoarthritis-pain-proceeding-well-901552.html Tue, 27 Aug 2019 12:35:00 -0400 https://www.proactiveinvestors.com/companies/news/901552/antibe-therapeutics-phase-2b-study-of-flagship-drug-atb-346-to-treat-osteoarthritis-pain-proceeding-well-901552.html Antibe Therapeutics to sell units to raise money to further develop lead osteoarthritis drug https://www.proactiveinvestors.com/companies/news/224378/antibe-therapeutics-to-sell-units-to-raise-money-to-further-develop-lead-osteoarthritis-drug-224378.html Tue, 23 Jul 2019 21:00:00 -0400 https://www.proactiveinvestors.com/companies/news/224378/antibe-therapeutics-to-sell-units-to-raise-money-to-further-develop-lead-osteoarthritis-drug-224378.html Antibe Therapeutics is looking to the future after successful past year https://www.proactiveinvestors.com/companies/news/313988/antibe-therapeutics-is-looking-to-the-future-after-successful-past-year-13988.html Thu, 04 Jul 2019 16:26:00 -0400 https://www.proactiveinvestors.com/companies/news/313988/antibe-therapeutics-is-looking-to-the-future-after-successful-past-year-13988.html Antibe Therapeutics hosts successful annual and special general meeting https://www.proactiveinvestors.com/companies/news/223238/antibe-therapeutics-hosts-successful-annual-and-special-general-meeting-223238.html Tue, 02 Jul 2019 23:56:00 -0400 https://www.proactiveinvestors.com/companies/news/223238/antibe-therapeutics-hosts-successful-annual-and-special-general-meeting-223238.html Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346 https://www.proactiveinvestors.com/companies/news/222800/antibe-therapeutics-updates-on-phase-2-progress-of-lead-drug-atb-346-222800.html Tue, 25 Jun 2019 17:30:00 -0400 https://www.proactiveinvestors.com/companies/news/222800/antibe-therapeutics-updates-on-phase-2-progress-of-lead-drug-atb-346-222800.html Antibe Therapeutics CEO Dan Legault on why the multibillion-dollar NSAID market needs disruption https://www.proactiveinvestors.com/companies/news/221077/antibe-therapeutics-ceo-dan-legault-on-why-the-multibillion-dollar-nsaid-market-needs-disruption-221077.html Fri, 07 Jun 2019 20:08:00 -0400 https://www.proactiveinvestors.com/companies/news/221077/antibe-therapeutics-ceo-dan-legault-on-why-the-multibillion-dollar-nsaid-market-needs-disruption-221077.html